Skip to main content

Table 2 Statistical evaluation of nuclear and cytosol staining between different time points

From: Immunohistochemical analysis in ethinylestradiol-treated breast cancers after prior long-term estrogen-deprivation therapy

A

Pre EE2 (n=10) mean (S.E.)

During + Post EE2 (n=8) mean (S.E.)

P-value

B

Pre EE2 (n=10) mean (S.E.)

During EE2 (n=3) mean (S.E.)

Post EE2 (N=5) mean (S.E.)

P-value

ER

nuc

166.7 (9.0)

68.3 (18.2)

0.0006**

ER

nuc

166.7 (9.0)

68.0 (28.8)

68.6 (26.1)

0.0024**

PgR

nuc

19.2 (15.8)

113.1 (24.1)

0.01*

PgR

nuc

19.2 (15.8)

171.3 (17.9)

78.2 (26.8)

0.0113*

Ki67

nuc

12.3 (1.96)

22.5 (5.82)

0.2

Ki67

nuc

12.3 (1.96)

10.0 (5.0)

30.0 (7.07)

0.052

BRCA1

nuc

96.6 (5.79)

64.8 (16.7)

0.3

BRCA1

nuc

96.6 (5.79)

57.3 (34.3)

69.4 (20.3)

0.56

cyto

0 (0)

36.6 (17.8)

0,047*

cyto

0 (0)

0 (0)

58.6 (23.9)

0.0126*

AR

nuc

119.2 (9.79)

44.2 (17.2)

0.039*

AR

nuc

119.2 (.979)

75.3 (28.7)

25.6 (18.7)

0.0065**

cyto

14.0 (9.79)

68.75 (15.7)

0.0097**

cyto

14.0 (9.79)

98.0 (1.52)

51.2 (22.0)

0.0092**

PI3K

cyto

83.3 (9.39)

95.0 (5.73)

0.31

PI3K

cyto

83.3 (9.3)

98.3 (1.66)

93.0 (9.41)

0.53

AKT

nuc

44.3 (11.3)

37.2 (12.6)

0.72

AKT

nuc

44.3 (11.3)

35.6 (25.0)

38.2 (16.0)

0.9

cyto

75.2 (9.69)

76.8 (11.8)

0.58

 

cyto

75.2 (9.69)

83.3 (12.0)

73.0 (18.3)

0.81

pAKT

nuc

7.2 (4.5)

17.2 (16.5)

0.63

pAKT

nuc

7.2 (4.5)

0 (0)

27.6 (26.3)

0.44

cyto

25.9 (11.4)

23.1 (15.1)

0.57

cyto

25.9 (11.4)

0 (0)

37.0 (22.6)

0.36

IGT1Rb

cyto

52.5 (13.3)

32.5 (16.1)

0.37

IGT1Rb

cyto

52.5 (13.3)

30.0 (30.0)

34.0 (21.4)

0.64

TUNEL

5.1 (2.42)

3.0 (1.26)

0.74

TUNEL

5.1 (2.44)

2.0 (2.0)

3.6 (1.74)

0.75

  1. The Wilcoxon test/the Kruskal-Wallis test was used to analyze the significance of differences between groups.
  2. nuc: nuclear, cyto: cytosol.
  3. *<0.05, **<0.01.